PDOX Models for Hematological Malignancies

Our novel PDOX procedure converts hematological malignancies into an orthotopic model for robust efficacy studies.

LIDE has established over 20 hematological malignancy patient-derived orthotopic xenografts (PDOXs) including AML, ALL, multiple myeloma, and different kinds of lymphoma.

Model ID

Sex

Age

PDX pathology

PDX s.c.

PDOX i.f.

LD1-0041-362047

Male

51

ALL

Y

Y

LD1-0041-362073

Male

64

ALL

Y

Y

LD1-0041-362356

Male

53

ALL

Y

Y

LD1-0041-362478

Male

15

ALL

Y

Y

LD1-1041-362519

Female

38

ALL

N/A

Y

LD1-0041-362021

Male

32

ALL

N/A

Y

LD1-0040-361280

Female

38

AML

Y

Y

LD1-0040-361293

Female

61

AML

Y

Y

LD1-0040-362349

Male

23

AML

Y

Y

LD1-0040-362384

Male

59

AML

N/A

Y

LD1-0040-362030

Female

56

AML

N/A

Y

LD1-0040-361780

Male

49

AML

N/A

Y

LD1-0040-362224

Male

75

AML

N/A

Y

LD1-0040-362369

Male

57

AML

Y

Y

LD1-0040-362393

Female

57

AML

Y

Y

LD1-0040-362499

Male

68

AML

N/A

Y

LD1-0040-362575

Female

31

AML

Y

Y

LD1-0026-362219

Male

24

Burkitt's lymphoma

Y

N/A

LD2-0026-200614

Male

/

CLL transit to DLBCL

Y

N/A

LD1-0026-362314

Male

51

Mantle cell lymphoma

Y

N/A

LD1-0029-361915

Male

62

Multiple myeloma

Y

N/A

LD1-0029-361847

Male

54

Multiple myeloma

Y

N/A

LD1-0006-370728

Male

68

Multiple myeloma

Y

N/A

Methodology

  1. Tumor cell suspension generated from fresh bone marrow biopsy or peripheral blood sample. 
  2. Suspensions are then inoculated into NCG mice intrafemorally.
  3. FACS analysis is performed periodically using whole blood from the mice to determine engraftment.
  4. Mice spleen, as the tumor source, are isolated for PDOX cryopreservation for further in vivo efficacy studies.


    PDOX of Hematological Malignancies
    Fig. Schematic of PDOX process for hematological malignancies